Company news

CSL Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CSL to Defend Class Action

October 21, 2026

CSL to Defend Class Action

October 21, 2026

CSL appoints Deborah Waterhouse as CEO & Managing Director

October 21, 2026

Appointment of New CEO

October 21, 2026

Appointment of New CEO

October 21, 2026

CSL dan Alentis umum perkongsian global untuk membangunkan dan mengkomersialkan lixudebart bagi penyakit buah pinggang dan hati yang jarang berlaku

October 8, 2026

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

October 4, 2026

CSL และ Alentis ประกาศความร่วมมือระดับโลก เพื่อพัฒนาและทำการตลาดยา lixudebart สำหรับโรคไตและตับที่พบได้ยาก

October 5, 2026

CSL enters exclusive agreement with Alentis Therapeutics

October 4, 2026

CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign

September 29, 2026

UK Government Strengthens Vaccine Partnership with CSL Seqirus, Introducing World-First Flu vaccine (aTIVc) and Extending Health Security Pandemic Agreement

September 21, 2026

Public Access to ANDEMBRY® (garadacimab) Expands Across Canada for the Prevention of Hereditary Angioedema (HAE) Attacks

September 22, 2026

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

September 10, 2026

CSL Enters Agreements with the U.S. Government to Lower Drug Prices and Support Investment in U.S. Manufacturing

August 31, 2026

World’s-First Battery-Powered Self-Unloading Bulk Carrier Now Operating in South Australia

August 26, 2026

CSL Results Presentation for FY2026

August 17, 2026

CSL FY2026 Results

August 17, 2026

CSL Statutory Accounts for FY2026

August 17, 2026

European Commission (EC) adopts decision to revoke marketing authorisation for TAVNEOS® (avacopan) in the European Union and European Economic Area countries

August 6, 2026

CSL Update on Enhanced Plasma Manufacturing

July 28, 2026

CSL Marks the Completion of the First Vessel in World-Leading Transhipment Fleet for Simandou Project

July 28, 2026

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

July 27, 2026

CSL Delivers World's First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations

June 12, 2026

CSL Delivers World’s First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations

June 12, 2026

CSL Takes Delivery of MV CSL Kuleana, Advancing CSL International Pool Newbuild Program

June 3, 2026

CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada

May 20, 2026

Vaccine Adjuvant Market Set to Boom Rapidly, Witnessing Strong Growth Through 2033 | CSL Limited, Seppic

May 14, 2026

CSL: Published Large U.S. Study Finds Comparable Effectiveness Between Adjuvanted and High-Dose Influenza Vaccines in Adults 65 Years and Older

May 13, 2026

CSL: Seqirus Signs Long-Term Agreement with the Pan American Health Organization (PAHO) to Advance Pandemic Influenza Preparedness in Latin America and the Caribbean

May 12, 2026

Interim CEO 90 Day Review and Financial Update

May 10, 2026

CSL Seqirus Signs Long-Term Agreement with The Pan American Health Organization to Advance Regional Influenza Protection in the Region of the Americas

March 11, 2026

CSL: Seqirus Signs Long-Term Agreement with The Pan American Health Organization (PAHO) to Advance Regional Influenza Protection in the Region of the Americas

March 10, 2026

CSL announces expansion of Illinois plasma therapy manufacturing facility

March 9, 2026

Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract

March 6, 2026

Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract

March 5, 2026

Neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia

February 16, 2026

CSL Half Year Results Investor Presentation

February 10, 2026

CSL Statutory Accounts for the Half Year Ended 31 December

February 10, 2026

CSL Half Year Results Announcement

February 10, 2026

Paul McKenzie retires, Gordon Naylor appointed interim CEO

February 10, 2026

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

December 7, 2025

CSL to invest approximately $1.5b in U.S. to manufacture plasma-derived therapies

November 18, 2025

CSL Capital Markets Day

November 4, 2025

Seqirus and Vaccine Industrial Company sign landmark Memorandum of Understanding with Ministry of Health to localize manufacturing of cell-based seasonal and pandemic influenza vaccines

October 30, 2025

CSL 2025 AGM Chair and CEO Speech and Presentation

October 27, 2025

CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)

October 26, 2025

Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines

October 21, 2025

CSL: Seqirus Presents Latest Research Across Leading Seasonal Influenza Vaccine Portfolio at ESWI 2025

October 17, 2025

CSL near-term emissions reduction targets validated by the SBTi

October 16, 2025

CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B

October 6, 2025

Older news releases →

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 82 decks. Every deck is listed under its year.